Limited Time Deal Gets You Pro at Half-Price
Limited Time Deal Gets You Pro at Half-Price
Exclusive News, Scanners, and Chat Power Pro Users to Win More This Deal Ends at 11:59pm
Exclusive News, Scanners, and Chat Power Pro Users to Win More This Deal Ends at 11:59pm
There is "tremendous excitement" about the therapeutic potential of psychedelics, says National Institute on Drug Abuse (NIDA) Director Nora Volkow. However, this top federal drug official emphasized that while promising, psychedelic treatments need more rigorous research and are "not magic."
During a Senate Appropriations Subcommittee hearing, Volkow explained that despite growing enthusiasm, current data does not fully support widespread use, reported Marijuana Moment. Sen. Brian Schatz (D-HI) inquired about current research status, stressing the need for evidence from agencies like NIDA before calling certain substances medicine. Meanwhile, Volkow stressed the importance of understanding optimal administration to ensure long-term benefits and minimize risks, underscoring the need for further studies.
Join industry leaders and pioneering experts as we explore the future of alternative mental health treatments at the upcoming Benzinga Cannabis Capital Conference in Chicago on Oct. 8-9. Get your tickets now before prices surge by following this link.
A newly posted page on the National Center for Complementary and Integrative Health (NCCIH) website highlighted the therapeutic potential of psilocybin, especially for treating alcohol use disorder, anxiety and depression. The page, “Psilocybin for Mental Health and Addiction: What You Need To Know,” outlines federally funded research into psilocybin’s effects on pain, migraine headaches and psychiatric disorders.
While psilocybin is a Schedule I controlled substance, it has received “breakthrough therapy” status from the Food and Drug Administration (FDA). The NCCIH emphasizes the need for more research, citing studies on short-term benefits and safety concerns. The page advises against using psilocybin as a substitute for professional medical care and encourages consulting healthcare providers about its use.
A new proposal from an Atlanta City Council member seeks to explore adding psilocybin and ketamine to the city's healthcare plan for mental health treatments. The resolution, sponsored by the majority of the council members, directs officials to assess the feasibility of these treatments for firefighters, police and other government workers.
Council member Liliana Bakhtiari, lead sponsor, stressed the need for alternative therapies due to the limited effectiveness of traditional treatments for conditions like PTSD and depression. The city's human resources department is tasked with reviewing scientific evidence, safety, cost and regulatory implications, with findings due by December 10.
"We should be offering our employees, and especially our first responders who are expected to be superhuman, the same amount of grace and providing them with a tool set to essentially overcome this issue," Bakhtiari told Axios.
Photo: Benzinga edit with photo by Alexander_Volkov and canbedone on Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!